Evolus (NASDAQ:EOLS) Hits New 12-Month Low - Here's Why

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) hit a new 52-week low on Wednesday . The company traded as low as $8.81 and last traded at $8.83, with a volume of 406801 shares traded. The stock had previously closed at $9.36.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on EOLS shares. Barclays lifted their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. Finally, HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Thursday.

Evolus Price Performance

The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a 50 day simple moving average of $12.91 and a 200 day simple moving average of $13.31. The stock has a market cap of $653.04 million, a P/E ratio of -11.29 and a beta of 0.97.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now owns 508,619 shares in the company, valued at $6,306,875.60. This represents a 1.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the transaction, the director now owns 32,183 shares in the company, valued at $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,575 shares of company stock worth $794,369. Insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new position in shares of Evolus in the fourth quarter valued at about $49,000. IFP Advisors Inc lifted its position in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus during the 4th quarter valued at approximately $106,000. Rafferty Asset Management LLC acquired a new position in shares of Evolus during the fourth quarter worth $115,000. Finally, Quantbot Technologies LP bought a new position in Evolus in the fourth quarter valued at about $118,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.